Sign In
1 Jun 2010 12:32
NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS
WINNERSH, UK: 1 June 2010
Vernalis plc (LSE : VER) ("Vernalis" or the "Company") announces that it has been informed that on 28 May 2010, the following director bought shares in the Company:
- Mr George Kennedy, Non-Executive and Senior Independent Director, purchased 100,000 Ordinary 1 pence shares at a price of 37 pence per share.
Following this transaction, Mr Kennedy will be the beneficial holder of 134,185 Ordinary 1 pence shares (0.13%) of the Company's current issued share capital.
Enquiries:
|
Vernalis |
+44 (0) 118 989 9360 |
|
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
|
|
|
Brunswick Group |
+44 (0) 20 7404 5959 |
|
Jon Coles Justine McIlroy Will Carnwath
|
|
|
Taylor Rafferty |
+44 (0) 20 7614 2900 |
|
Rob Newman Faisal Kanth |
|
About Vernalis:
Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eleven candidates in development, eight of which are designated priority programmes. Five of these priority programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Biogen Idec, Chiesi, Endo, GSK, Menarini, Novartis and Servier.
For further information about Vernalis, please visit www.vernalis.com.
Follow the stocks
